• Advisory Committee on Immunization Practices (ACIP) makes 2016-17 recommendation against the live attenuated influenza vaccine (LAIV4), and changes to recommendations for people with egg allergy.

Key recommendations

• Routine annual vaccination is recommended for everyone aged ≥6 months without contraindications.
• Inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations.
• Recombinant influenza vaccine (RIV) will be available in a trivalent formulation (RIV3).

Read More